Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Transcenta Holding Limited ( (HK:6628) ).
Transcenta Holding Limited announced its interim results for the six months ended June 30, 2025, revealing a decrease in revenue primarily due to a decline in CDMO services. Despite this, the company saw an increase in other income from government subsidies and a reduction in research and development expenses, which contributed to a decrease in overall losses. The company’s strategic reprioritization of resources and pipeline advancement efforts were highlighted as key factors in the financial performance during this period.
The most recent analyst rating on (HK:6628) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Transcenta Holding Limited stock, see the HK:6628 Stock Forecast page.
More about Transcenta Holding Limited
Transcenta Holding Limited is a biotechnology company focused on the development and manufacturing of innovative biologics. The company operates in the biopharmaceutical industry, providing contract development and manufacturing organization (CDMO) services and engaging in research and development activities.
Average Trading Volume: 3,153,886
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.62B
Find detailed analytics on 6628 stock on TipRanks’ Stock Analysis page.